[1]鲍 楠,张蓬杰,朱燕亭,等.2型糖尿病肾病患者血清lncRNAMEG3，lncRNASOX2OT水平表达与肾功能及预后的相关性研究[J].现代检验医学杂志,2025,40(03):84-90.[doi:10.3969/j.issn.1671-7414.2025.03.016]
　BAO Nan,ZHANG Pengjie,ZHU Yanting,et al.Correlation between Serum lncRNA MEG3, lncRNA SOX2OT Level Expression and Renal Function and Prognosis in Patients with Type 2 Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2025,40(03):84-90.[doi:10.3969/j.issn.1671-7414.2025.03.016]
点击复制

2型糖尿病肾病患者血清lncRNAMEG3，lncRNASOX2OT水平表达与肾功能及预后的相关性研究()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年03期
页码:
84-90
栏目:
论著
出版日期:
2025-05-15

文章信息/Info

Title:
Correlation between Serum lncRNA MEG3, lncRNA SOX2OT Level Expression and Renal Function and Prognosis in Patients with Type 2 Diabetic Nephropathy
文章编号:
1671-7414（2025）03-084-07
作者:
鲍 楠1，张蓬杰1，朱燕亭1，闻苗苗2
（1.陕西省人民医院肾内科，西安 710068；2.西安市第五医院检验科，西安 710082）
Author(s):
BAO Nan1，ZHANG Pengjie1，ZHU Yanting1，WEN Miaomiao2
(1. Department of Nephrology，Shaanxi Provincial People’s Hospital，Xi’an 710068，China；2. Department of Clinical Laboratory，Xi’an Fifth Hospital， Xi’an 710082，China)
关键词:
2型糖尿病肾病; 长链非编码RNA母系表达基因3; 长链非编码RNA SRY盒转录因子2重叠转录本; 肾功能
分类号:
R587.2；R392.11
DOI:
10.3969/j.issn.1671-7414.2025.03.016
文献标志码:
A
摘要:
目的探讨2型糖尿病肾病（T2DN）患者血清长链非编码RNA母系表达基因3（lncRNAMEG3），长链非编码RNASRY盒转录因子2重叠转录本（lncRNASOX2OT）水平表达与肾功能及预后的相关性。方法选取2019年1月～2021年1月陕西省人民医院收治的T2DN患者205例（T2DN组），单纯2型糖尿病（T2DM）患者150例（T2DM组）和体检健康者150例（对照组），根据三年预后将T2DN患者分为不良预后组（n=73）和良好预后组（n=132）。检测血清lncRNAMEG3和lncRNASOX2OT水平；相关性分析采用Pearson分析法；影响因素采用Logistic回归分析；受试者工作特征（ROC）曲线评价预测价值。结果T2DN组血清lncRNAMEG3（2.20±0.32）高于T2DM组（1.49±0.20）和对照组（1.00±0.06），lncRNASOX2OT（0.50±0.11）低于T2DM组（0.73±0.15）和对照组（1.05±0.16），差异具有统计学意义（t=23.960，45.332；28.745，16.670，均P＜0.01）。T2DN患者血清lncRNAMEG3水平与估计肾小球滤过率（eGFR）呈负相关，与尿清蛋白/肌酐比值（UACR）水平呈正相关（r=-0.532，0.485，均P＜0.01）；血清lncRNASOX2OT水平与eGFR呈正相关，与UACR呈负相关（r=0.421，-0.517，均P＜0.01）。T2DN患者不良预后的危险因素为慢性肾脏病分期4期、UACR和lncRNAMEG3（Waldχ2=6.360，6.678，16.652，均P＜0.05），保护因素为eGFR，lncRNASOX2OT（Waldχ2=5.463，11.797，均P＜0.05）。血清lncRNAMEG3联合lncRNASOX2OT预测的曲线下面积高于lncRNAMEG3，lncRNASOX2OT单独预测，差异具有统计学意义（Z=3.841，3.337，均P＜0.05）。结论血清lncRNAMEG3水平升高和lncRNASOX2OT水平降低与T2DN患者肾功能降低及不良预后有关，两者联合检测对T2DN患者不良预后有较高预测价值。
Abstract:
Objective To investigate the relationship between the serum levels of lncRNA mathematically expressed gene 3(lncRNA MEG3)，lncRNA SRY-box transcription factor 2 overlapping transcript (lncRNA SOX2OT) and renal function and prognosis in patients with type 2 diabetic nephropathy (T2DN). Methods 205 patients with T2DN admitted to Shaanxi Provincial People’s Hospital from January 2019 to January 2021 (T2DN group) were selected, as well as 150 simple T2DM patients (T2DM group) and 150 healthy individuals (control group) during the same period. And the patients with T2DN were classified into the poor prognosis group(n=73) and the good prognosis group(n=132) according to the 3-year prognosis. Serum levels of lncRNA MEG3 and lncRNA SOX2OT were detected. Pearson analysis was used for correlation analysis; The influencing factors were analyzed using logistic regression, and the predictive value was evaluated using the subject’s work characteristic curve. Results The serum lncRNA MEG3 (2.20 ± 0.32) in the T2DN group was higher than that in the T2DM group (1.49 ± 0.20) and control group (1.00 ± 0.06), and the lncRNA SOX2OT (0.50 ± 0.11) was lower than that in the T2DM group (0.73 ± 0.15) and control group (1.05 ± 0.16), the differences were statistically significant(t=23.960, 45.322; 28.745, 16.670,all P<0.01). The serum lncRNA MEG3 levels in T2DN patients were negatively correlated with estimated glomerular filtration rate (eGFR) and positively correlated with urinary albumin/creatinine ratio (UACR) levels (r=-0.532, 0.485, all P<0.01)and the serum lncRNA SOX2OT level was positively correlated with eGFR and negatively correlated with UACR (r=0.421, -0.517,all P<0.01).The risk factors for poor prognosis in T2DN patients were chronic kidney disease stage 4，UACR and lncRNA MEG3（Wald χ2=6.360， 6.678，16.652，all P＜0.05）while the protective factors were eGFR，lncRNA SOX2OT（Wald χ2=5.463, 11.797, all P＜0.05）. The AUC predicted by the combination of serum lncRNA MEG3 and lncRNA SOX2OT was larger than that predicted by lncRNA MEG3 and lncRNA SOX2OT predicts separately, and the differences were statistically significant (Z=3.841, 3.337, all P<0.05).Conclusion Elevated serum lncRNA MEG3 levels and reduced lncRNA SOX2OT levels are associated with reduced renal function and poor prognosis in patients with T2DN, and the combination of the two tests has a high predictive value for poor prognosis in patients with T2DN.

参考文献/References:

[1] SUN Hong, SAEEDI P, KARURANGA S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045 [J]. Diabetes Research and Clinical Practice, 2022, 183: 109119.
[2] 陈筱涛, 刘韵, 龙碧莹, 等. 2型糖尿病肾病患者血清代谢组学分析构建预后预测模型研究[J]. 现代检验医学杂志, 2023, 38(3): 97-102, 164. CHEN Xiaotao, LIU Yun, LONG Biying, et al. Analysis of serum metabolomics model in type 2 diabetic nephropathy[J]. Journal of Modern Laboratory Medicine, 2023, 38(3): 97-102, 164.
[3] 中华医学会全科医学分会, 《中国糖尿病肾脏病基层管理指南》编写专家组. 中国糖尿病肾脏病基层管理指南[J]. 中华全科医师杂志, 2023, 22(2):146-157. Chinese Society of General Practice，Writing Group of Guideline for Primary Care of Diabetes Kidney Disease in China. Guideline for primary care of diabetes kidney disease in China [J]. Chinese Journal of General Practit ioners,2023,22(2):146-157.
[4] 刘慧, 钟娇影, 刘杰, 等.糖尿病肾病患者血清miR-495-3p和lncRNA NEAT1表达水平及其与患者预后的相关性研究[J].现代检验医学杂志, 2023, 38(3):35-39. LIU Hui, ZHONG Jiaoying, LIU Jie, et al. Study on the expression levels of serum miR-495-3p and lncRNA NEAT1 in diabetic nephropathy and their relationship with prognosis of patients[J]. Journal of Modern Laboratory Medicine, 2023, 38(3): 35-39.
[5] XU Binwu, RAO Yao, WANG Le, et al. LncRNA MEG3 inhibits renal fibrinoid necrosis of diabetic nephropathy via the MEG3/miR-21/ORAI1 axis[J]. Molecular Biology Reports, 2023, 50(4): 3283-3295.
[6] ZHANG Yan, CHANG Baochao, ZHANG Jiqiang, et al. LncRNA SOX2OT alleviates the high glucose-induced podocytes injury through autophagy induction by the miR-9/SIRT1 axis[J]. Experimental and Molecular Pathology, 2019, 110: 104283.
[7] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中华糖尿病杂志, 2018, 10(1):4-67. Diabetes Society of Chinese Medical Association. Chinese guideline for the prevention and treatment of type 2 diabetes mellitus(2017 edition) [J]. Chinese Journal of Diabetes Mellitus, 2018, 10(1): 4-67.
[8] 中华医学会糖尿病学分会微血管并发症学组.中国糖尿病肾脏疾病防治临床指南[J]．中华糖尿病杂志, 2019,11(1):15-28. the Microvascular Complications Group of Chinese Diabetes Association. Chinese clinical practice guideline of diabetic kidney disease [J]. Chinese Journal of Diabetes Mellitus, 2019, 11(1): 15-28.
[9] FLOEGE J, BARBOUR S J, CATTRAN D C, et al. Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference[J]. Kidney International, 2019, 95(2): 268-280.
[10] 苗素芳, 张维娜, 张姣姣. 血清Zonulin和Metrnl水平与糖尿病肾病患者病情及预后的关系[J]. 新疆医科大学学报, 2023,46(11):1513-1518. MIAO Sufang, ZHANG Weina, ZHANG Jiaojiao.Relationship between serum Zonulin and Metrnl levels and condition and prognosis of diabetic nephropathy patients[J]. Journal of Xinjiang Medical University, 2023, 46(11): 1513-1518.
[11] 中华医学会肾脏病学分会专家组.糖尿病肾脏疾病诊断、预后评估和生物标志物应用专家共识[J].中华肾脏病杂志, 2022, 38(8):771-784. Expert group of Chinese Society of Nephrology. Expert consensus on diagnosis, prognosis assessment and application of biomarkers in diabetic kidney disease [J]. Chinese Journal of Nephrology, 2022, 38(8): 771-784.
[12] 中华医学会肾脏病学分会专家组.终末期糖尿病肾脏病肾替代治疗的中国指南[J].中华肾脏病杂志, 2022,38(1):62-75. Expert group of Chinese Society of Nephrology. Chinese guidelines for renal replacement therapy in diabetic end-stage renal disease [J]. Chinese Journal of Nephrology, 2022, 38(1): 62-75.
[13] THURLOW J S, JOSHI M, YAN Guofen, et al. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy[J]. American Journal of Nephrology, 2021, 52(2): 98-107.
[14] 牛和慧, 史林超, 柳辉.长非编码RNA MEG3的调控机制与抑癌功能新进展[J].生命科学, 2022,34(6):676-684. NIU Hehui, SHI Linchao, LIU Hui. The recent progress on regulation mechanism and tumor suppressor function of long non-coding RNA MEG3 [J]. Chinese Bulletin of Life Sciences, 2022, 34(6): 676-684.
[15] ZHU Xiang, WU Yuanbo, ZHOU Jian, et al. Upregulation of lncRNA MEG3 promotes hepatic insulin resistance via increasing FoxO1 expression[J]. Biochemical and Biophysical Research Communications, 2016, 469(2):319-325.
[16] DIETER C, LEMOS N E, GIRARDI E, et al. The rs3931283/PVT1 and rs7158663/MEG3 polymorphisms are associated with diabetic kidney disease and markers of renal function in patients with type 2 diabetes mellitus[J]. Molecular Biology Reports, 2023, 50(3):2159-2169.
[17] ALREFAI A A, KHADER H F, ELBASUONY H A, et al. Evaluation of the expression levels of lncRNAs H19 and MEG3 in patients with type 2 diabetes mellitus[J]. Molecular Biology Reports, 2023, 50(7): 6075-6085.
[18] ZHA Fangfang, QU Xiaolu, TANG Bo, et al. Long non-coding RNA MEG3 promotes fibrosis and inflammatory response in diabetic nephropathy via miR-181a/Egr-1/TLR4 axis[J]. Aging (Albany NY), 2019, 11(11): 3716-3730.
[19] LUO Qimei, XIA Xi, LUO Qingqing, et al. Long noncoding RNA MEG3-205/Let-7a/MyD88 axis promotes renal inflammation and fibrosis in diabetic nephropathy[J]. Kidney Diseases Basel Switzerland, 2022, 8(3): 231-245.
[20] WANG Ying, WU Nayiuan, LUO Xia, et al. SOX2OT, a novel tumor-related long non-coding RNA [J]. Biomedicine & Pharmacotherapy, 2020, 123: 109725.
[21] ZHANG Xiaoxue, SHANG Jin, WANG Xiaoyang, et al. Microarray analysis reveals long non-coding RNA SOX2OT as a novel candidate regulator in diabetic nephropathy[J]. Molecular Medicine Reports, 2018, 18(6): 5058-5068.
[22] 于薇.LncRNA SOX20T抑制糖尿病肾病系膜细胞基质分泌的机制研究[D].郑州:郑州大学, 2021. YU Wei. Mechanism of lncRNA SOX20T inhibiting mesangial matrix secretion in diabetic nephropathy[D]. Zhengzhou：Zhengzhou University，2021.
[23] CHEN Ke, YU Bo, LIAO Jie. LncRNA SOX2OT alleviates mesangial cell proliferation and fibrosis in diabetic nephropathy via Akt/mTOR-mediated autophagy[J]. Molecular Medicine, 2021, 27(1): 71.
[24] YE Gang, HU Manli, XIAO Ling. Forkhead box A2-mediated lncRNA SOX2OT up-regulation alleviates oxidative stress and apoptosis of renal tubular epithelial cells by promoting SIRT1 expression in diabetic nephropathy[J]. Nephrology (Carlton, Vic.), 2023, 28(3): 196-207.
?

相似文献/References:

[1]沈伟兴,汤佳瑾,傅　鹏.2型糖尿病肾病患者外周血 microRNA-155水平与肾小球滤过率的相关性研究[J].现代检验医学杂志,2022,37(01):12.[doi:10.3969/j.issn.1671-7414.2022.01.003]
　SHEN Wei-xing,TANG Jia-jin,FU Peng.Correlation between microRNA-155 Level in Peripheral Blood and Glomerular Filtration Rate in Patients with Type 2 DiabeticNephropathy[J].Journal of Modern Laboratory Medicine,2022,37(03):12.[doi:10.3969/j.issn.1671-7414.2022.01.003]
[2]贺 炜,刘泓键,易艳霞,等.血清骨生成诱导因子及miR-22-3p 表达水平对2 型糖尿病肾病早期诊断价值研究[J].现代检验医学杂志,2023,38(02):37.[doi:10.3969/j.issn.1671-7414.2023.02.007 ]
　HE Wei,LIU Hong-jian,YI Yan-xia,et al.Value of Serum Osteoinductive Factor and miR-22-3p Expression in the Early Diagnosis of Type 2 Diabetic Nephropathy[J].Journal of Modern Laboratory Medicine,2023,38(03):37.[doi:10.3969/j.issn.1671-7414.2023.02.007 ]

备注/Memo

备注/Memo:
基金项目：陕西省自然科学基础研究计划项目（2021JQ-905）。
作者简介：鲍楠(1983-)，女，硕士研究生，主治医师，研究方向：肾内相关疾病，E-mail：baonan830106@163.com。
通讯作者：闻苗苗(1986-)，女，本科，主管检验师，研究方向：临床检验，E-mail：273260454@qq.com。
更新日期/Last Update: 2025-05-15